Skip to main content

Integrating Health: a One Health Approach to Antimicrobial Resistance and Sustainable Practices

Cover image for Research Topic "Integrating Health: a One Health Approach to Antimicrobial Resistance and Sustainable Practices"
83kviews
Editorial: Integrating health: a One Health approach to antimicrobial resistance and sustainable practices
Editorial22 September 2026
Editorial: Integrating health: a One Health approach to antimicrobial resistance and sustainable practices

Although doxyPEP can be effective in certain populations, its broader implications for antimicrobial resistance require continued monitoring. The potential benefits of preventing infection must therefore be considered alongside the possibility of increasing antimicrobial selection pressure and altering microbial communities.We can conclude that AMR is a complex phenomenon that cannot be effectively controlled by a single discipline, intervention, or sector. Its drivers and consequences span human and animal health, agriculture, and the environment, making an integrated One Health approach essential. Effective action requires strong governance, responsible antimicrobial use, antimicrobial stewardship, infection prevention, improved diagnostics, genomic surveillance, education, vaccination, and continued research into sustainable alternatives. Such integration can help identify emerging threats earlier and allow interventions to be targeted where they are most needed.

484 views

ORIGINAL RESEARCH
21 January 2026
Veterinarians' attitudes, knowledge, and practices about antibiotic use in animals: questionnaire design and reliability

2,033 views

1 citations

ORIGINAL RESEARCH
8 May 2026
Comparative effectiveness of hand hygiene modalities in reducing microbial colonization on nurses’ hands in surgical settings in Jordan
Hanadi Dakhilallah, 5 more and Boshra Karem Mohamed El-Sayed

2,052 views

ORIGINAL RESEARCH
13 November 2025
The dltC gene contributes to polyhexamethylene biguanide resistance in Staphylococcus aureus
Chenyang Guo, 9 more and Huaixin Zheng

2,469 views

3 citations

ORIGINAL RESEARCH
24 October 2025
Impact of the COVID-19 pandemic on vancomycin-resistant Enterococcus bloodstream infections: a 6-year study in Western Greece
Maria Lagadinou, 12 more and Markos Marangos

4,231 views

7 citations

Global prevalence and antibiotic resistance profiles of carbapenem-resistant Pseudomonas aeruginosa reported from 2014 to 2024: a systematic review and meta-analysis
SYSTEMATIC REVIEW
21 July 2025
Global prevalence and antibiotic resistance profiles of carbapenem-resistant Pseudomonas aeruginosa reported from 2014 to 2024: a systematic review and meta-analysis
Tsepo Ramatla, 5 more and George Khasapane
IntroductionCarbapenem-resistant Pseudomonas aeruginosa (CRPA) represents a global threat, but the global distribution of carbapenem resistant bacteria remains a critical issue in public health.MethodsWe conducted a systematic review and meta-analysis on the global pooled prevalence estimate (PPE) of CRPA and their antibiotic resistance. The systematic review protocol was registered with PROSPERO (CRD42024579654). This study was carried out following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Heterogeneity between studies was assessed using Cochrane Q test and I2 test statistics based on the random effects model. Comprehensive meta-analysis software v4.0 was used to analyze the pooled prevalence of CRPA.ResultsA total of 163 studies (both clinical and screening samples) containing a total of 58,344 cases from 39 countries were included in this study. The overall PPE of CRPA was 34.7% (95% CI: 0.316–0.37.8) for both clinical and screening samples. Meropenem had a PPE of 31.2% (95% CI: 0.272–0.352) and imipenem had the lowest PPE of 27.7% (95% CI: 0.238–0.319). Japan had the highest PPE at 98.2% (95% CI: 0.482–0.100) of CRPA, and the lowest was observed for Saudi Arabia at 13.9% (95% CI: 0. 064–0. 277). CRPA is widespread on five continents except Australia and Antarctica, while the highest PPE is in Europe at 47.6% (95% CI: 0.359–0.595) and the lowest in Asia at 32, 8% (95% CI: 0.293–0.364). The relatively higher PPE of CRPA was observed in Europe during the year interval 2014–2017 at 95.4% (95% CI: 0.388–0.999), followed by Africa from the year 2022–2024 with 38.5% (95% CI: 0.243–0.550). Ceftazidime was significantly higher in studies conducted before 2019 with a PPE of 44.7% (95% CI: 0.246% – 0.668), while CRPA after 2019 had a higher resistance to cefoperazone/sulbactam with a PPE of 17.3% (95% CI: 0.050–0.455).DiscussionThis review indicates that the prevalence of CRPA is generally high and varies significantly between countries. To prevent the emergence of CRPA and antibiotic resistance, future initiatives should prioritise strengthening laboratory capacity for early detection of antibiotic resistance.

11,084 views

57 citations

ORIGINAL RESEARCH
10 June 2025
Reporting antimicrobial susceptibility and detection of carbapenemase production in single and double carbapenemase-producing Gram-negative clinical isolates: a nationwide proficiency study
Felipe Fernández-Cuenca, 4 more and Álvaro Pascual

3,233 views

1 citations